北京时间
China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站
一 | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。
二 |
三 | 公开报名通道将在6月内开启，届时会在“国家地理杂志”公众号和宁德时代公众号进行公布。
“四化”方案发布！绘制景区零碳升级路线图发布会上，宁德时代依托在零碳科技领域的深厚积累，提出以“四化”为核心的零碳文旅解决方案，助力景区实现节能减排、降本增效最大化，为文旅行业提供可持续可复制推广的零碳升级范本：交通运营「电动化」：通过动力电池及充换电技术创新帮助目的地实现水陆空交通领域的全面电动化转型，降低交通运营成本。景区供能「绿电化」： 通过光、储、充、放等零碳核心技术创新，构建智能微电网，让目的地实现“绿电自由”的同时，余电可为游客提供充电服务或反向上网，获得额外收益。
四 |
能碳管理「智能化」： 通过数字能源及碳排放管理平台的搭建，既能为目的地“源网荷储”各系统的安全可靠运行保驾护航，又能助力目的地更加高效地开发碳汇项目、参与碳市场交易。零碳旅游「商业化」： 开发以新能源体验为特色的旅游线路，吸引注重环保的高消费游客群体；不断推出新能源化的配套设施及健身发电单车、全电户外装备等终端体验产品，为目的地吸引更多优质流量。同时，宁德时代携手首批上榜的武夷山国家公园正式启动零碳景区改造项目。这标志着榜单发布从“评选”迈入“共建”的实质性阶段。
五 | 预计未来将有20余家车企加入联盟，为目的地带来旅游人次与收入的双增长，并为超过10万车友提供先锋的零碳旅游体验。
未来，宁德时代将与更多景区开展深度合作，加速先进零碳技术的示范应用，实现零碳科技在文旅产业的经济价值最大化，推动零碳文旅新经济的高质量发展。
六 |
七 |
Current article:http://jfrpge.yizhougengcuohei.cyou/news/20260826_664.html
Published on:08:51:09